ArticleInflammatory bowel diseases2010
Overexpression of translocator protein in inflammatory bowel disease: potential diagnostic and treatment value.
Article in Inflammatory bowel diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Role of Mitochondria in Inflammatory Bowel Diseases: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Microglial Activation in Nociplastic Pain: From Preclinical Models to PET Neuroimaging and Implications for Targeted Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Translocator protein facilitates neutrophil-mediated mucosal inflammation in inflammatory bowel diseases.World journal of gastroenterology · 2025Article
- Translocator Protein 18 kDa (TSPO): A Promising Molecular Target for Image-Guided Surgery of Solid Cancers.Advanced pharmaceutical bulletin · 2024Review
- Imaging Agents for PET of Inflammatory Bowel Disease: A Review.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Review
- Advances in macrophage-targeting nanoparticles for the diagnosis and treatment of inflammatory bowel disease.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2023Review
- PET assessment of acute gastrointestinal graft versus host disease.Bone marrow transplantation · 2023Review
- [Bone marrow transplantation · 2022Article
- Mitochondrial translocator protein deficiency exacerbates pathology in acute experimental ulcerative colitis.Frontiers in physiology · 2022Article
- TSPO protein binding partners in bacteria, animals, and plants.Journal of bioenergetics and biomembranes · 2021Review
- Uric acid drives intestinal barrier dysfunction through TSPO-mediated NLRP3 inflammasome activation.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Article
- Targeting Mitochondria in Tumor-Associated Macrophages using a Dendrimer-Conjugated TSPO Ligand that Stimulates Antitumor Signaling in Glioblastoma.Biomacromolecules · 2020Article
- Translocator protein 18 kDa: a potential therapeutic biomarker for post traumatic stress disorder.Metabolic brain disease · 2020Review
- Astrocytic TSPO Upregulation Appears Before Microglial TSPO in Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2020Article
- Control and dysregulation of redox signalling in the gastrointestinal tract.Nature reviews. Gastroenterology & hepatology · 2019Review
- The Mitochondrial GenesInternational journal of molecular sciences · 2018Article
- Characteristics of electroencephalogram signatures in sedated patients induced by various anesthetic agents.Journal of dental anesthesia and pain medicine · 2017Review
- Evaluating [Molecular imaging and biology · 2017Article
- TSPO PET Imaging: From Microglial Activation to Peripheral Sterile Inflammatory Diseases?Contrast media & molecular imaging · 2017Review
- Role of molecular imaging in the management of patients affected by inflammatory bowel disease: State-of-the-art.World journal of radiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundInflammatory bowel diseases (IBDs), such as ulcerative colitis and Crohn's disease, are chronic inflammatory disorders that increase the risk for colorectal cancer. The mitochondrial translocator protein (TSPO) is a high-affinity drug- and cholesterol-binding protein expressed in the colon and its expression is increased in colon cancers. The aim of this study was to investigate TSPO expression in IBD biopsies and to establish an animal model of IBD to examine the role of TSPO. In addition, we evaluated the potential use of TSPO drug ligands in diagnosing and treating IBD.
methodsTSPO expression in IBD biopsies was evaluated using immunohistochemistry. IBD was induced in a rat experimental model via treatment with dextran sodium sulfate (DSS). Colon morphology, TSPO expression, and proinflammatory cytokine production were evaluated in addition to the effect of TSPO drug ligands on disease pathology.
resultsTSPO protein levels were elevated in the enterocytes of IBD biopsies. TSPO expression was localized to the enterocyte mitochondria. DSS treatment induced a time-dependent phenotype mimicking IBD with tissue injury and subsequent tissue regeneration. Coadministration of DSS and the TSPO drug ligands PK 11195 or Ro5-4864 increased both the rate of colon ulceration and regeneration, whereas administration of the TSPO drug ligand flunitrazepam partially prevented this pathology. These data correlated with changes in proinflammatory cytokine plasma levels, as well as increased cytokine production and secretion from the colon.
conclusionsTSPO may serve as a marker of the IBD repair process, and TSPO drug ligands should be further evaluated for IBD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.